Q1 Research Tools & Consumables Earnings Review: First Prize Goes to Waters Corporation (NYSE:WAT)Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Waters Corporation (NYSE:WAT...
2 Large-Cap Stocks to Keep an Eye On and 1 We IgnoreLarge-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...
Q1 Earnings Roundup: Mettler-Toledo (NYSE:MTD) And The Rest Of The Research Tools & Consumables SegmentThe end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how research tools & consu...
Waters Corporation (WAT): Buy, Sell, or Hold Post Q1 Earnings?Over the last six months, Waters Corporation’s shares have sunk to $357.08, producing a disappointing 7.2% loss - a stark contrast to the S&P 500’s 7.8% gain...
Q1 Rundown: Avantor (NYSE:AVTR) Vs Other Research Tools & Consumables StocksAs the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the research tools & consumables industry, including Avantor (NYS...
1 Healthcare Stock to Consider Right Now and 2 We Brush OffPersonal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
2 Unpopular Stocks That Should Get More Attention and 1 We AvoidWhen Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Q1 Earnings Highs And Lows: Bruker (NASDAQ:BRKR) Vs The Rest Of The Research Tools & Consumables StocksThe end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a...
Research Tools & Consumables Stocks Q1 Results: Benchmarking Danaher (NYSE:DHR)Looking back on research tools & consumables stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Danaher (
NYSE:DHR) and its p...
The 5 Most Interesting Analyst Questions From Waters Corporation’s Q1 Earnings CallWaters Corporation’s first quarter saw a strong market response, as the company delivered results ahead of Wall Street’s revenue and earnings expectations de...
WAT Q1 Deep Dive: Revenue Outperformance and Integration Drive Upbeat OutlookScientific instruments company Waters Corporation (
NYSE:WAT) beat Wall Street’s revenue expectations in Q1 CY2026, but sales fell by 12.8% year on year to $1...
Waters Corporation (NYSE:WAT) Surprises With Strong Q1 CY2026, Stock SoarsScientific instruments company Waters Corporation (
NYSE:WAT) reported Q1 CY2026 results exceeding the market’s revenue expectations, but sales fell by 12.8% ...
Waters Corporation (WAT) Reports Q1: Everything You Need To Know Ahead Of EarningsScientific instruments company Waters Corporation (
NYSE:WAT) will be announcing earnings results this Tuesday morning. Here’s what you need to know. Waters C...
3 of Wall Street’s Favorite Stocks with Promising ProspectsWall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
2 Large-Cap Stocks Worth Investigating and 1 We QuestionLarge-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...
The “New BD”: A Deep-Dive Research Report on Becton, Dickinson and Company (BDX) in 2026As of April 3, 2026, the medical technology landscape is undergoing a radical transformation, and few companies embody this evolution more than Becton, Dickinson and Company (
NYSE: BDX). Known colloquially as BD, the firm has spent the last two years shedding its skin, moving from a broad-based healthcare conglomerate to a high-growth, high-margin "pure-play" medical [...]
The Evolution of a MedTech Giant: A Deep Dive into Becton, Dickinson and Company (BDX)As of April 1, 2026, Becton, Dickinson and Company (
NYSE: BDX), commonly known as BD, finds itself at a historic crossroads. For decades, BD was viewed as a diversified healthcare conglomerate—a "steady Eddie" of the MedTech world that provided everything from basic syringes to complex diagnostic laboratory equipment. However, the recent completion of the Biosciences [...]
